Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment

To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA,...

Descripción completa

Detalles Bibliográficos
Autores: Vela, Paloma|||0000-0001-8566-5172, Sanchez-Piedra, Carlos, Pérez-García, Carolina|||0000-0002-6695-6406, Castro-Villegas, Ma Carmen, Freire, Mercedes, Mateo, Lourdes|||0000-0002-6394-2949, Diaz-Torne, Cesar|||0000-0001-6275-7699, Bohórquez, Cristina, Blanco-Madrigal, Juan M., Ros-Vilamajo, Inmaculada, Gómez, Silvia, Caño, Rocio, Sánchez-Alonso, Fernando, Díaz-González, Federico|||0000-0002-4139-9295, Gómez-Reino, Juan J.
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:284609
Acceso en línea:https://ddd.uab.cat/record/284609
https://dx.doi.org/urn:doi:10.1186/s13075-020-02231-x
Access Level:acceso abierto
Palabra clave:Ankylosing spondylitis
Biologics
Elderly-onset rheumatoid arthritis
Psoriatic arthritis
Rheumatoid arthritis
Descripción
Sumario:To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA, and classified as young (< 25 years old), adult (25-64 years old), elderly (65-75 years old) or very elderly (.

Similares en LA Referencia